CD20 (Cluster of Differentiation 20), also called B lymphocyte antigen CD20, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells, in human it is encoded by MS4A1 gene. CD20 plays a role in the development and differentiation of B-cells into plasma cells.its function is to enable optimal B-cell immune response, specifically against T-independent antigens.CD20 is expressed on all stages of B cell development except the first and last. It has been found that associated with B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Therefore CD20 have been considered as a therapeutic target of monoclonal antibodies such as rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
CAR-NK-1-M327-2 | Anti-CD20 scFv h(CD28) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28 | Lentiviral | NK cell | |
CAR-NK-1-M327-G | Anti-CD20 scFv h(FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-1-M327-Z | Anti-CD20 scFv h(CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M327-2Z | Anti-CD20 scFv h(CD28-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M327-4G | Anti-CD20 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD4-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M327-4Z | Anti-CD20 scFv h(CD4-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD4-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M327-8Z | Anti-CD20 scFv h(CD8-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD8-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M327-BG | Anti-CD20 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M327-BZ | Anti-CD20 scFv h(41BB-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M327-CZ | Anti-CD20 scFv h(b2c-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-b2c-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M327-2BZ | Anti-CD20 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M327-2XZ | Anti-CD20 scFv h(CD28-OX40-CD3ζ) CARNK, pCDCAR1 | Human | rituximab | Chimeric | scFv-CD28-OX40-CD3ζ | Lentiviral | NK cell | |
CAR-T-1-M302-2 | Anti-CD20 scFv h(CD28) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28 | Lentiviral | T cell | |
CAR-T-1-M302-G | Anti-CD20 scFv h(FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | |
CAR-T-1-M302-Z | Anti-CD20 scFv h(CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M302-2G | Anti-CD20 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-M302-2Z | Anti-CD20 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M302-4G | Anti-CD20 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-M302-4Z | Anti-CD20 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M302-8Z | Anti-CD20 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD8-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M302-BZ | Anti-CD20 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M302-CZ | Anti-CD20 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-b2c-CD3ζ | Lentiviral | T cell | |
CAR-T-3-M302-2BZ | Anti-CD20 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-3-M302-2XZ | Anti-CD20 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | 1F5 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |
CAR-LC227 | Anti-CD20 h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Mouse | scFv-41BB-CD3ζ | Lentiviral | NK cell | ||
CAR-LC354 | Anti-MS4A1 h(41BB-CD3ζ, Her2t) Marked CAR, pCDCAR1 | Human | Human | scFv-41BB-CD3ζ/Her2t | Lentiviral | T cell | ||
CAR-MZ017 | Anti-CD20 (Leu-16) h(CD3ζ) CAR, pCDCAR1 | Human | Leu-16 | Human | scFv-CD3ζ | Lentiviral | T cell | |
CAR-MZ018 | Anti-CD20 (Leu-16) h(CD28-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Leu-16 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
CAR-MZ055 | Anti-CD20 (Ofatumumab) h(FcγRIII) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-FcγRIII | Lentiviral | NK cell | |
CAR-MZ056 | Anti-CD20 (Ofatumumab) h(CD3ζ) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-CD3ζ | Lentiviral | NK cell | |
CAR-MZ057 | Anti-CD20 (Ofatumumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Ofatumumab | Human | scFv-CD28-CD3ζ | Lentiviral | NK cell | |
CAR-LY078 | Anti-CD20 (2H7) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Monkey | 2H7 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
CAR-LY1718 | Anti-CD20(2H7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human, Monkey | 2H7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP8836 | Anti-CD20 (BA0185) h(CD28-CD3ζ) CAR, pcDCAR1 | EBV | BA0185 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP8837 | Anti-CD20 (BA0185) h(4-1BB-CD3ζ) CAR, pcDCAR1 | EBV | BA0185 | Rabbit | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP8465 | A uniCAR [Anti-GCN4 CAR], with a Fab-based CAR Adaptor [Anti-CD20 (Ofatumumab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8478 | A uniCAR [Anti-FITC CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8485 | A uniCAR [Anti-biotin CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Cetuximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8486 | A uniCAR [Anti-CD16 (FCGR3A) 158(V/V)(FCGR3A)-CD3TM/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8491 | A uniCAR [Anti-CD16 CAR], with a mAb-based CAR Adaptor [Anti-CD20 (Obinutuzumab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-YF706 | Anti-CD20 (2B8) h(CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD3ζ | Lentiviral vector | T Cell | |
CAR-YF765 | Anti-CD20 (2B8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | |
CAR-YF820 | Anti-CD20 (2B8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T Cell | |
CAR-YF877 | Anti-CD20 (2B8) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | |
CAR-YF935 | Anti-CD20 (2B8) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 2B8 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | |
CAR-ZP8489 | A uniCAR [anti-CD16 (FCGR3A) V158 variant-CD8ɑ/41BB/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8492 | A uniCAR [anti-CD16 (FCGR3A) 48H and V158 variant-CD 28TM/CD28ICD/CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8497 | A uniCAR [anti-CD16A (V158) CD8TM/CD28-CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector | |||||
CAR-ZP8498 | A uniCAR [anti-CD16A-41BB/CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System | Mature B cell neoplasms | Lentiviral vector |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE